VIDEO: Novel immune targets in lung cancer ‘generate excitement’
In this video, Vivek Subbiah, MD, associate professor at The University of Texas MD Anderson Cancer Center, discussed results from KEYNOTE-604.
The phase 3 study evaluated the overall survival and progression-free survival of patients with extensive-stage small-cell lung cancer (SCLC) who were treated with pembrolizumab (Keytruda, Merck) plus etoposide and platinum compared with patients treated with placebo plus etoposide and platinum.
“The findings showed that the immunotherapy/chemotherapy combination showed a significant improvement in progression-free survival, but the overall survival was not found to be significant when compared to placebo and chemotherapy,” Subbiah explained.
He also highlighted CITYSCAPE, a primary analysis of anti-TIGIT antibody tiragolumab (Roche) plus atezolizumab (Tecentriq, Genentech/Roche) compared with placebo plus atezolizumab as a first-line treatment for patients with PD-L1-selected non-small cell lung cancer (NSCLC).
“Promising new immune targets always generate excitement, and this is particularly true for this TIGIT,” Subbiah said.
References:
- Rodriguez-Abreu D, et al. Abstract 9503. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
- Rudin CM, et al. Abstract 9001. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
Collapse
Healio Interview